Welcome!

News Feed Item

MediPoint: Sports Medicine - US Analysis and Market Forecasts

NEW YORK, April 22, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Sports Medicine - US Analysis and Market Forecasts
http://www.reportlinker.com/p02081704/MediPoint-Sports-Medicine---US-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

MediPoint: Sports Medicine - US Analysis and Market Forecasts

Summary

This report focuses on the sports medicine market, which includes implants and arthroscopic capital equipment. The orthopedic sports medicine market has been estimated in this report and covers the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India. The report provides unmet needs, future adoption and compound annual growth rates (CAGR). GlobalData's analysis shows that while the orthopedics implant market is mature, sports medicine is an area with the potential for significant international growth. With the market, the US remains to be the largest market with the EU to follow and growing. The APAC region while markedly smaller has a large potential patient population.The top six to seven market leaders continue to dominate the market through technological innovation and investment in establishing strong distribution networks. The major opportunity lies within technological advancement and the clinical trials to prove effectiveness of new techniques.

The US sports medicine market is a strong and growing market, with prevalence of sports-related injury rising most rapidly among the young and old. The biggest player in sports medicine in the US remains Arthrex, leading with a 21% market share. This company has the strongest brand identity and offers a wide selection of products, which makes it competitive and able to maintain its market share.

Scope

- An overview of sports medicine, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized the US sports medicine market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for sports medicine.
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the sports medicine sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

- Understand the trends shaping and driving the US sports medicine market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in the US sports medicine market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in the US sports medicine market landscape? Identify, understand and capitalize.
1 Table of Contents

2 Introduction 20
2.1 Catalyst 21
2.2 Related Reports 22
2.3 Upcoming Related Reports 22
3 Clinical Outcomes 23
3.1 Conservative Treatments 23
3.1.1 Immobilization and Bracing 24
3.1.2 Physical Therapy 24
3.1.3 Muscle Stimulation 25
3.2 Drug Therapy 25
3.2.1 Nutritional Supplements 26
3.2.2 Analgesics and NSAIDs 26
3.2.3 Corticosteroids 26
3.2.4 Viscosupplementation 26
3.3 Soft Tissue Repair 27
3.4 Arthroscopy 29
3.5 Plates and Screws 30
3.6 Joint Replacement 30
4 Industry Overview 32
4.1 Overview 32
4.2 Procedure Trends 33
4.2.1 US 33
4.3 Market Access 35
4.3.1 US 35
4.4 Disputes and Settlements 40
4.4.1 Smith & Nephew Granted an Injunction Against Arthrex 40
4.4.2 KFx Medical and Smith & Nephew Enter Into Licensing Agreement 40
4.4.3 KFx Medical Wins Patent Infringement Lawsuit Against Arthrex 40
4.4.4 ArthroCare and Smith & Nephew Settle Legal Disputes 40
4.5 Mergers, Acquisitions, Partnerships, and Other Deals 40
4.5.1 Stryker Acquires Pivot Medical 40
4.5.2 Smith & Nephew Announces Acquisition of ArthroCare 41
4.5.3 Smith & Nephew Acquires Plato Grup Assets 41
4.5.4 Smith & Nephew Announces Acquisition of Its Brazil Distribution Business 41
4.5.5 Kensey Nash Acquires Minority Stake in Orteq Sports Medicine 41
4.5.6 Tornier Acquires C2M Medical 42
4.5.7 Tornier Signs Licensing Agreement with T.A.G. Medical Products Corporation 42
4.5.8 Biomet Acquires Cartilix 42
4.5.9 Biomet Sports Medicine Enters Into Deal With Marc Tec 42
4.6 Economic Impact 42
4.6.1 Developed Countries 42
4.6.2 Emerging Markets 45
5 Unmet Needs 46
5.1 Long-Term Clinical Data 46
5.1.1 Hip Arthroscopic Implants Clinical Data 46
5.1.2 Rotator Cuff Injury Clinical Data 46
5.2 Cartilage and Meniscal Repair Product Development 47
5.2.1 Knee Meniscus Treatment 47
5.2.2 Hip Cartilage Product Development 49
5.3 Biologics for Faster Healing 50
5.4 Standardization and Improvement of Instruments 51
5.4.1 Hip and Shoulder Instrumentation 51
5.4.2 Screwdriver Standardization 51
5.5 Fellowship Training Programs 52
5.6 Advanced Materials Research 53
5.7 Bioabsorbable Technology Development 54
5.8 Centralization 56
5.9 Need for Cost-Containment 56
5.10 Suture Anchor Product Development 57
6 Market Opportunity Analysis 59
6.1 Adding More Training Programs 59
6.2 Product Line Extensions 59
6.3 Lack of Pricing Pressure in Sports Medicine 60
6.4 Mergers and Acquisitions 61
6.5 Seasonality of Sports Medicine 62
6.6 Emerging Markets 62
6.7 Minimally-Invasive Surgical Preference 63
7 Market Drivers, Barriers and Substitutes 64
7.1 Driver: Rising Prevalence 64
7.1.1 Sports-Related Injuries 64
7.1.2 Aging 64
7.1.3 Trauma 65
7.2 Driver: Hip Arthroscopy 66
7.2.1 Femoroacetabular Impingement Growth 67
7.2.2 Hip Arthroscopy Fellowship Training Programs 68
7.3 Driver: Knee and Shoulder Arthroscopy 68
7.4 Driver: Revision Surgery 69
7.5 Driver: Patient Demand and Awareness 70
7.6 Driver: Orthobiologics Development 71
7.6.1 Bone Grafts 71
7.6.2 Platelet-Rich Plasma 72
7.7 Driver: Rising Competition and Innovation Through Small Players 72
7.8 Driver: Materials Development 72
7.8.1 Composite Materials and Biopolymers 73
7.8.2 Bioabsorbables 73
7.8.3 Metallic Alloys in Orthopedics 74
7.9 Barrier: Arthroscopy's Questionable Outcomes 75
7.9.1 Hip Arthroscopy 75
7.9.2 Knee Arthroscopy 76
7.10 Barrier: Steep Learning Curve 77
7.11 Barrier: Reimbursement 77
7.12 Barrier: Burden of Rising Regulation 79
7.13 Barrier: Proving Efficacy 80
7.14 Barrier: Medical Device Excise Tax 81
7.15 Substitute: Open Surgery Versus Minimally-Invasive Arthroscopy 81
7.16 Substitute: Conservative Treatment Options 82
8 Competitive Assessment 83
8.1 Overview 83
8.2 Marketed Products in Sports Medicine 83
8.2.1 Arthrex 83
8.2.2 ArthroCare Corporation 90
8.2.3 Biomet 94
8.2.4 ConMed Corporation 98
8.2.5 DePuy Mitek 103
8.2.6 Smith & Nephew 106
8.2.7 Stryker 109
8.2.8 Tornier 111
9 Pipeline Assessment 113
9.1 Overview 113
9.2 Product Profiles 113
9.2.1 Bioretec Drug-Releasing Screws 113
9.2.2 Nanova Bioabsorbable Bone Screws 113
9.2.3 MinInvasive Arthroscopic Suture Passer 113
9.2.4 SpineSmith Pipeline 114
9.2.5 DePuy Mitek FMS VUE 114
9.2.6 Pivot Medical Hip Arthroscopy System 114
9.2.7 University of Florida Shoulder Labral Anchor Delivery System 114
9.2.8 University of California at San Diego Cartilage Regeneration Device 114
10 Clinical Trials to Watch 115
10.1 Overview 115
10.2 Can Shoulder Arthroscopy Work (CSAW) Study 115
10.3 Arthroscopy in the Treatment of Degenerative Medial Meniscus Tear 115
10.4 Knee Arthroscopy Cohort Southern Denmark 116
10.5 Hip Arthroscopy Versus Conservative Management of Femoroacetabular Impingement 116
10.6 Femoroacetabular Impingement Randomized Controlled Trial 117
10.7 Multicenter ACL Revision Study (MARS) 117
10.8 Arthroscopic Versus Open Stabilization for Traumatic Shoulder Instability 118
10.9 Microfracture in the Knee Study 118
10.10 Single- Versus Double-Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears 119
10.11 Early Surgery Versus Conservative Therapy for Meniscal Injuries in Older Patients (ESCAPE) 119
10.12 Arthroscopic Rotator Cuff Repair of Full Thickness Tears With and Without Arthroscopic Acromioplasty 120
10.13 Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma 121
10.14 Tibial Tunnel Widening in ACL Reconstruction-Comparing Two Bioscrews 121
11 Current and Future Players 122
11.1 Trends in Corporate Strategy 122
11.2 Company Profiles 123
11.2.1 Arthrex 123
11.2.2 ArthroCare Corporation 125
11.2.3 Biomet 127
11.2.4 ConMed Corporation 130
11.2.5 DePuy Companies 132
11.2.6 Smith & Nephew 134
11.2.7 Stryker 136
11.2.8 Tornier 138
11.2.9 Wright Medical Group 141
11.2.10 Other Key Players in Sports Medicine 144
12 Market Outlook 149
12.1 Company Market Share 149
12.1.1 Overview 149
12.1.2 US 149
12.2 US Market Outlook 150
13 Appendix 153
13.1 Bibliography 153
13.2 Abbreviations 162
13.3 Research Methodology 166
13.3.1 Overview 166
13.3.2 Coverage 166
13.3.3 Secondary Research 166
13.4 Physicians and Specialists Included in this Study 167
13.4.1 Dr. Henry D.E. Atkinson 167
13.4.2 Dr. Joshua Alpert 167
13.4.3 Dr. Andrea Ferretti 167
13.4.4 Dr. Alejandro Gonzalez Della Valle 168
13.4.5 Dr. Andreas Imhoff 168
13.4.6 Dr. Marcello Zaia Oliveira 168
13.4.7 Dr. Vidhya Ravi 168
13.4.8 Dr. Elvire Servien 168
13.4.9 Dr. Yotaro Yamakado 168
13.5 Primary Research 169
13.5.1 Primary Research - Key Opinion Leader Interviews 169
13.5.2 Primary Research - Physician and Industry Interviews 169
13.5.3 Expert Panel Validation 170
13.6 Forecasting Methodology 170
13.7 About the Authors 172
13.7.1 Analysts 172
13.7.2 Global Head of Healthcare 173
13.8 About MediPoint 174
13.9 About GlobalData 174
13.10 Disclaimer 174

1.1 List of Tables

Table 1: Most Common Soft Tissue Injuries to the Extremities in Sports Medicine 28
Table 2: Growth Rates for Arthroscopy by Joint in the US, 2013-2020 34
Table 3: Medicare ICD-9 Diagnosis Codes for Common Sports Medicine Injuries, 2013 38
Table 4: Medicare National Adjusted Reimbursement Rates for Common Sports Medicine Injuries for Hospital Outpatient Treatment, 2013 39
Table 5: Medicare DRG Payments to Hospitals for Common Sports Medicine Injuries, 2013 39
Table 6: Direct, Indirect, and Intangible Costs of Orthopedics 44
Table 7: Potential Market for Meniscus Treatment Types 48
Table 8: Metal Implant CharacteristicsThat Can Be Improved 74
Table 9: Arthrex Shoulder Implants 85
Table 10: Arthrex, Shoulder Instrumentation 86
Table 11: Arthrex, Knee Sutures and Suture Anchors 86
Table 12: Arthrex, Knee Graft Fixation Devices and Meniscal Products 87
Table 13: Arthrex, Hip Implants and Instruments 88
Table 14: Arthrex, Arthroscopy Procedure Capital Equipment 89
Table 15: Arthrex, Implants SWOT Analysis 89
Table 16: Arthrex, Instrumentation SWOT Analysis 90
Table 17: Arthrocare, Suture Implants 91
Table 18: ArthroCare, Suture Management Products 92
Table 19: ArthroCare, Cruciate Ligament Graft Fixation Products 93
Table 20: ArthroCare, Capital Equipment and Instruments 93
Table 21: ArthroCare, Implants SWOT Analysis 94
Table 22: Arthrocare, Instruments and Capital Equipment SWOT Analysis 94
Table 23: Biomet, Shoulder Arthroscopy Products 95
Table 24: Biomet, Knee Arthroscopy Products 96
Table 25: Biomet's Other Joints Arthroscopy Products 97
Table 26: Biomet, Capital Equipment Sports Medicine Products 97
Table 27: Biomet Implants SWOT Analysis 98
Table 28: Biomet, Capital Equipment SWOT Analysis 98
Table 29: ConMed, Shoulder Arthroscopy Products 99
Table 30: ConMed, Knee Arthroscopy Products 100
Table 31: ConMed, Small Joint and Hip Arthroscopy Products 101
Table 32: ConMed, Instruments and Capital Equipment 102
Table 33: ConMed, Implants SWOT Analysis 102
Table 34: ConMed, Capital Equipment SWOT Analysis 103
Table 35: DePuy Mitek, Fixation Devices 104
Table 36: DePuy, Mitek Instruments 105
Table 37: DePuy Mitek, Capital Equipment 105
Table 38: DePuy Mitek Implants, SWOT Analysis 106
Table 39: DePuy Mitek, Capital Equipment SWOT Analysis 106
Table 40: Smith & Nephew, Fixation Devices 107
Table 41: Smith & Nephew, Instruments and Capital Equipment 108
Table 42: Smith & Nephew Implants, SWOT Analysis 108
Table 43: Smith & Nephew, Capital Equipment SWOT Analysis 109
Table 44: Stryker, Fixation Devices 109
Table 45: Stryker, Instrumentation 110
Table 46: Stryker, Capital Equipment 110
Table 47: Stryker, Fixation Devices SWOT Analysis 111
Table 48: Stryker, Instrumentation and Capital Equipment SWOT Analysis 111
Table 49: Tornier Sports Medicine Products 112
Table 50: Tornier, Product Family SWOT Analysis 112
Table 51: Can Shoulder Arthroscopy Work (CSAW) 115
Table 52: Arthroscopy in the Treatment of Degenerative Medial Meniscus Tear 116
Table 53: Knee Arthroscopy Cohort Southern Denmark 116
Table 54: Hip Arthroscopy Versus Conservative Management of Femoroacetabular Impingement 117
Table 55: Femoroacetabular Impingement Randomized Controlled Trial 117
Table 56: Multicenter ACL Revision Study (MARS) 118
Table 57: Arthroscopic Versus Open Stabilization for Traumatic Shoulder Instability 118
Table 58: Results at 10 to 14 Years After Microfracture in the Knee 119
Table 59: Single Versus Double Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears 119
Table 60: Early Surgery Versus Conservative Therapy for Meniscal Injuries in Older Patients (ESCAPE) 120
Table 61: Arthroscopic Rotator Cuff Repair of Full Thickness Tears With and Without Arthroscopic Acromioplasty 120
Table 62: Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma in Large to Massive Tears 121
Table 63: Tibial Tunnel Widening in Anterior Cruciate Ligament Reconstruction Comparing Two Bioscrews 121
Table 64: Company Profile - Arthrex 124
Table 65: SWOT Analysis - Arthrex 125
Table 66: Company Profile - ArthroCare Corporation 126
Table 67: SWOT Analysis - ArthroCare Corporation 127
Table 68: Company Profile - Biomet 128
Table 69: SWOT Analysis - Biomet 129
Table 70: Company Profile - ConMed Corporation 131
Table 71: SWOT Analysis - ConMed Corporation 132
Table 72: Company Profile - DePuy Companies 133
Table 73: SWOT Analysis - DePuy Companies 134
Table 74: Company Profile - Smith & Nephew 135
Table 75: SWOT Analysis - Smith & Nephew 136
Table 76: Company Profile - Stryker 137
Table 77: SWOT Analysis - Stryker 138
Table 78: Company Profile - Tornier 139
Table 79: SWOT Analysis - Tornier 140
Table 80: Company Profile - Wright Medical Group 142
Table 81: SWOT Analysis - Wright Medical Group 143
Table 82: Other Sports Medicine Companies in the US Market 144
Table 83: Other Sports Medicine Companies in the EU Market 145
Table 84: Other Sports Medicine Companies in the APAC Market 147
Table 85: US Sports Medicine Sales Forecast ($m), 2011-2020 152
Table 86: Primary Research Interviews Completed in Sports Medicine 170

1.2 List of Figures

Figure 1: Global Arthroscopic Procedure Volumes by Joint, 2011-2020 32
Figure 2: US Arthroscopic Procedure Volumes, 2011-2020 33
Figure 3: US Arthroscopic Procedure Volumes by Joint, 2011-2020 34
Figure 4: Sources of Orthopedic Trauma (%) (n=103) 66
Figure 5: US Market Share for Arthroscopy, 2012 150
Figure 6: US Sports Medicine Sales Forecast ($m), 2011-2020 152

To order this report: MediPoint: Sports Medicine - US Analysis and Market Forecasts
http://www.reportlinker.com/p02081704/MediPoint-Sports-Medicine---US-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
SYS-CON Events announced today that Telecom Reseller has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
"We're developing a software that is based on the cloud environment and we are providing those services to corporations and the general public," explained Seungmin Kim, CEO/CTO of SM Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
SYS-CON Events announced today that CrowdReviews.com has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5–7, 2018, at the Javits Center in New York City, NY. CrowdReviews.com is a transparent online platform for determining which products and services are the best based on the opinion of the crowd. The crowd consists of Internet users that have experienced products and services first-hand and have an interest in letting other potential buye...
"CA has been doing a lot of things in the area of DevOps. Now we have a complete set of tool sets in order to enable customers to go all the way from planning to development to testing down to release into the operations," explained Aruna Ravichandran, Vice President of Global Marketing and Strategy at CA Technologies, in this SYS-CON.tv interview at DevOps Summit at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
"Codigm is based on the cloud and we are here to explore marketing opportunities in America. Our mission is to make an ecosystem of the SW environment that anyone can understand, learn, teach, and develop the SW on the cloud," explained Sung Tae Ryu, CEO of Codigm, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...